|
|
Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China |
Huanping Wang1,2, Haitao Meng1,2, Jinghan Wang1,2, Yinjun Lou1,2, Yile Zhou1, Peipei Lin3, Fenglin Li1, Lin Liu1,2, Huan Xu1,2, Min Yang1,2, Jie Jin1,2() |
1. Institute of Hematology, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China 2. Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang Province, Hangzhou 310003, China 3. Department of Hematology, Taizhou Central Hospital, Taizhou 318000, China |
|
|
Abstract This study aimed to investigate the prevalence, clinical characteristics, and prognostic impact of 1p32.3 deletion in patients with newly diagnosed multiple myeloma (MM). A retrospective analysis was conducted on 411 patients with newly diagnosed MM; among which, 270 received bortezomib-based therapies, and 141 received thalidomide-based therapies. Fluorescence in situ hybridization (FISH) was performed to detect six cytogenetic abnormalities, namely, del(1p32.3), gain(1q21), del(17p13), del(13q14), t(4;14), and t(11;14). Results showed that 8.3% of patients with MM were detected with del(1p32.3) and had significantly more bone marrow plasma cells (P = 0.025), higher β2-microglobulin levels (P = 0.036), and higher lactate dehydrogenase levels (P = 0.042) than those without del(1p32.3). Univariate analysis showed that patients with del(1p32.3) under thalidomide-based therapies (median PFS 11.6 vs. 31.2 months, P = 0.002; median OS 16.8 vs. 45.9 months, P <0.001) were strongly associated with short progression-free survival (PFS) (P = 0.002) and overall survival (OS) (P <0.001). Multivariate analysis revealed that del(1p32.3) remained a powerful independent factor with worse PFS (P = 0.006) and OS (P = 0.016) for patients under thalidomide-based treatments. Patients with del(1p32.3) under bortezomib-based treatments tended to have short PFS and OS. In conclusion, del(1p32.3) is associated with short PFS and OS in patients with MM who received thalidomide- or bortezomib-based treatments.
|
Keywords
1p32.3 deletion
1q21 gain
prognosis
multiple myeloma
FISH
bortezomib
thalidomide
|
Corresponding Author(s):
Jie Jin
|
Just Accepted Date: 11 September 2019
Online First Date: 29 November 2019
Issue Date: 08 June 2020
|
|
1 |
FW Cremer, J Bila, I Buck, M Kartal, D Hose, C Ittrich, A Benner, MS Raab, AC Theil, M Moos, H Goldschmidt, CR Bartram, A Jauch. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005; 44(2): 194–203
https://doi.org/10.1002/gcc.20231
pmid: 16001433
|
2 |
R Fonseca, E Blood, M Rue, D Harrington, MM Oken, RA Kyle, GW Dewald, B Van Ness, SA Van Wier, KJ Henderson, RJ Bailey, PR Greipp. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101(11): 4569–4575
https://doi.org/10.1182/blood-2002-10-3017
pmid: 12576322
|
3 |
JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, A Dispenzieri, R Fonseca, T Sher, RA Kyle, Y Lin, SJ Russell, S Kumar, PL Bergsagel, SR Zeldenrust, N Leung, MT Drake, P Kapoor, SM Ansell, TE Witzig, JA Lust, RJ Dalton, MA Gertz, AK Stewart, SV Rajkumar, A Chanan-Khan, MQ Lacy; Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88(4): 360–376
https://doi.org/10.1016/j.mayocp.2013.01.019
pmid: 23541011
|
4 |
WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, JS Miguel, P Sonneveld, M Cavo, S Usmani, BG Durie, H Avet-Loiseau; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28(2): 269–277
https://doi.org/10.1038/leu.2013.247
pmid: 23974982
|
5 |
R Fonseca, PL Bergsagel, J Drach, J Shaughnessy, N Gutierrez, AK Stewart, G Morgan, B Van Ness, M Chesi, S Minvielle, A Neri, B Barlogie, WM Kuehl, P Liebisch, F Davies, S Chen-Kiang, BG Durie, R Carrasco, O Sezer, T Reiman, L Pilarski, H Avet-Loiseau; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23(12): 2210–2221
https://doi.org/10.1038/leu.2009.174
pmid: 19798094
|
6 |
BA Walker, PE Leone, L Chiecchio, NJ Dickens, MW Jenner, KD Boyd, DC Johnson, D Gonzalez, GP Dagrada, RK Protheroe, ZJ Konn, DM Stockley, WM Gregory, FE Davies, FM Ross, GJ Morgan. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116(15): e56–e65
https://doi.org/10.1182/blood-2010-04-279596
pmid: 20616218
|
7 |
H Chang, X Qi, A Jiang, W Xu, T Young, D Reece. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010; 45(1): 117–121
https://doi.org/10.1038/bmt.2009.107
pmid: 19448682
|
8 |
H Chang, Y Ning, X Qi, J Yeung, W Xu. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007; 139(1): 51–54
https://doi.org/10.1111/j.1365-2141.2007.06750.x
pmid: 17854306
|
9 |
WJ Chng, MA Gertz, TH Chung, S Van Wier, JJ Keats, A Baker, PL Bergsagel, J Carpten, R Fonseca. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24(4): 833–842
https://doi.org/10.1038/leu.2010.21
pmid: 20220778
|
10 |
B Hebraud, X Leleu, V Lauwers-Cances, M Roussel, D Caillot, G Marit, L Karlin, C Hulin, C Gentil, F Guilhot, L Garderet, T Lamy, S Brechignac, B Pegourie, J Jaubert, M Dib, AM Stoppa, C Sebban, C Fohrer, J Fontan, C Fruchart, M Macro, F Orsini-Piocelle, G Lepeu, C Sohn, J Corre, T Facon, P Moreau, M Attal, H Avet-Loiseau. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014; 28(3): 675–679
https://doi.org/10.1038/leu.2013.225
pmid: 23892719
|
11 |
F Li, L Hu, Y Xu, Z Li, S Yi, Z Gu, C Li, M Hao, K Ru, F Zhan, A Zetterberg, W Yuan, T Cheng, L Qiu. Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma. Leukemia 2016; 30(5): 1197–1201
https://doi.org/10.1038/leu.2015.254
pmid: 26460211
|
12 |
PE Leone, BA Walker, MW Jenner, L Chiecchio, G Dagrada, RK Protheroe, DC Johnson, NJ Dickens, JL Brito, M Else, D Gonzalez, FM Ross, S Chen-Kiang, FE Davies, GJ Morgan. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008; 14(19): 6033–6041
https://doi.org/10.1158/1078-0432.CCR-08-0347
pmid: 18829482
|
13 |
A Dib, TR Peterson, L Raducha-Grace, A Zingone, F Zhan, I Hanamura, B Barlogie, J Shaughnessy Jr, WM Kuehl. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div 2006; 1(1): 23
https://doi.org/10.1186/1747-1028-1-23
pmid: 17049078
|
14 |
FM Ross, H Avet-Loiseau, G Ameye, NC Gutiérrez, P Liebisch, S O’Connor, K Dalva, S Fabris, AM Testi, M Jarosova, C Hodkinson, A Collin, G Kerndrup, P Kuglik, D Ladon, P Bernasconi, B Maes, Z Zemanova, K Michalova, L Michau, K Neben, NE Hermansen, K Rack, A Rocci, R Protheroe, L Chiecchio, HA Poirel, P Sonneveld, M Nyegaard, HE Johnsen; European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012; 97(8): 1272–1277
https://doi.org/10.3324/haematol.2011.056176
pmid: 22371180
|
15 |
KD Boyd, FM Ross, BA Walker, CP Wardell, WJ Tapper, L Chiecchio, G Dagrada, ZJ Konn, WM Gregory, GH Jackson, JA Child, FE Davies, GJ Morgan; NCRI Haematology Oncology Studies Group. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17(24): 7776–7784
https://doi.org/10.1158/1078-0432.CCR-11-1791
pmid: 21994415
|
16 |
GP Kaufman, MA Gertz, A Dispenzieri, MQ Lacy, FK Buadi, D Dingli, SR Hayman, P Kapoor, JA Lust, S Russell, RS Go, YL Hwa, RA Kyle, SV Rajkumar, SK Kumar. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia 2016; 30(3): 633–639
https://doi.org/10.1038/leu.2015.287
pmid: 26487275
|
17 |
A Lakshman, M Alhaj Moustafa, SV Rajkumar, A Dispenzieri, MA Gertz, FK Buadi, MQ Lacy, D Dingli, AL Fonder, SR Hayman, MA Hobbs, WI Gonsalves, YL Hwa, P Kapoor, N Leung, RS Go, Y Lin, TV Kourelis, JA Lust, SJ Russell, SR Zeldenrust, RA Kyle, SK Kumar. Natural history of t(11;14) multiple myeloma. Leukemia 2018; 32(1): 131–138
https://doi.org/10.1038/leu.2017.204
pmid: 28655925
|
18 |
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, KC Anderson, WJ Chng, P Moreau, M Attal, RA Kyle, J Caers, J Hillengass, J San Miguel, NW van de Donk, H Einsele, J Bladé, BG Durie, H Goldschmidt, MV Mateos, A Palumbo, R Orlowski. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127(24): 2955–2962
https://doi.org/10.1182/blood-2016-01-631200
pmid: 27002115
|
19 |
SV Rajkumar. Multiple myeloma: 2018 update on diagnosis, risk—stratification, and management. Am J Hematol 2018; 93(8): 1091–1110
https://doi.org/10.1002/ajh.25117
pmid: 30400719
|
20 |
N Grzasko, R Hajek, M Hus, S Chocholska, M Morawska, K Giannopoulos, K Czarnocki, A Druzd-Sitek, B Pienkowska-Grela, J Rygier, L Usnarska-Zubkiewicz, D Dytfeld, T Kubicki, A Jurczyszyn, M Korpysz, A Dmoszynska. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leuk Lymphoma 2017; 58(9): 2089–2100
https://doi.org/10.1080/10428194.2016.1272684
pmid: 28092996
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|